PHARMACY

Genentech appoints new CEO
Genentech has named Alexander Hardy its CEO effective March 1, succeeding Bill Anderson.
NACDS weighs in on DIR fee reform in comments to CMS
NACDS is making the case that DIR fee reform is necessary in its comments to the Centers for Medicare and Medicaid Services, which recently issued a proposed rule focused on reducing patient out-of-pocket costs.

Amerigen gets FDA nod for generic Adderall XR

Amerigen’s generic of Shire’s extended-release ADHD drug will be available in 5-, 10-, 15-, 20-, 25- and 30-mg dosage strengths.
Dr. Reddy’s launches generic Diprivan

Dr. Reddy's is offering generic Diprivan (propofol) injectable emulsion, which had a market value of roughly $310 million for the year ended November 2018, according to IQVIA data.
Lannett launches 2 generics through recently inked deals

Lannett is launching generic Syprine and Comtan, which had a market value of $140 million, and $23 million, respectively.
Benzer Pharmacy names chief technology, marketing officer

Meghann Chilcott, formerly of OrderInsite, is joining Benzer Pharmacy as its chief technology and marketing officer.
Survey: Patients concerned about taking medication properly

Patients who lack confidence in taking medications properly blame it on a lack of time with physicians, according to a new survey from e-prescribing and medication management solutions company DrFirst.
CVS Health's Accordant gets NCQA case management accreditation

Accordant, a CVS Health company, has received its second three-year accreditation for case management from NCQA, demonstrating compliance with the organization's case management program standards.
Easing open enrollment uncertainty for patients

AmerisourceBergen’s Kelly Gasper discusses how pharmacists can play an integral role in helping patients navigate open enrollment and the potential changes it brings.
Slayback Pharma intros generic Makena

Slayback’s generic Makena also is the first generic of Amag Pharmaceuticals’ drug in a multidose vial.